First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.
Keiko TanimuraTakayuki TakedaNobutaka KataokaAkihiro YoshimuraKentaro NakanishiYuta YamanakaHiroshige YoshiokaRyoichi HondaKiyoaki UryuMototaka FukuiYusuke ChiharaShota TakeiHayato KawachiTadaaki YamadaNobuyo TamiyaNaoko OkuraTakahiro YamadaJunji MuraiShinsuke ShiotsuTakayasu KurataTakayama KoichiPublished in: Cancers (2023)
CIT is recommended for patients with NSCLC with 1-49% PD-L1 expression because it significantly improved OS and PFS compared to SEQ. CIT had limited benefits in patients with <1% PD-L1 expression, and the median PFS-2 in the SEQ group was significantly longer than the median PFS in the CIT group. These findings will help physicians select the most suitable treatment option for patients with NSCLC, considering PD-L1 expressions.
Keyphrases
- small cell lung cancer
- genome wide
- rna seq
- single cell
- advanced non small cell lung cancer
- poor prognosis
- primary care
- locally advanced
- cross sectional
- dna methylation
- squamous cell carcinoma
- binding protein
- clinical trial
- long non coding rna
- epidermal growth factor receptor
- smoking cessation
- rectal cancer
- tyrosine kinase